You're browsing as a guest. Sign in to unlock all features.
CRBP
CRBP·Biotechnology·United States
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets...
1 Total1 External0 In-site
CRBPCRBP
2026-03-25🏥 HealthcarePitch
Externalby mack885 · Other
mack885 on CRBP (CRBP)
公司名称：Corbus Pharmaceuticals
主要经营地：美国
详细生意模式：生物制药，3条无关联管线(肿瘤/减肥)；CRB-701 Nectin-4 ADC在HNSCC中47.6% ORR(vs Padcev 23.9%)；CRB-913 CB1逆激动剂
护城河：🟡中：多管线分散风险+现金充足，但临床成功概率低且竞品存在
估值水平：负EV($161M市值 vs $178M现金)，$15M/Q burn
EV/Market Cap：TEV -$9M / MCap $153M
网络观点：负EV安全边际+CRB-701展示47.6%缓解率；目标$13.25(+53%)
AI观点：现金覆盖市值罕见，CRB-701低毒性高ORR数据强劲(vs Padcev)；mid-2026耐久性数据风险高；CRB-913减重数据偏弱(2.9%)；负EV保护，高风险高回报
原文日期：2026-03-25
作者简介：VIC价值投资者